Researchers at Massachusetts General Hospital (MGH) have discovered that the interferon gamma receptor (IFNgR) signaling pathway is critical for susceptibility of glioblastoma tumors to killing by CAR T-cell immunotherapy.
Cellular Immunotherapy Program
Explore the Cellular Immunotherapy Program
The mission of the Mass General Cellular Immunotherapy Program is to invent, develop, administer, and understand engineered immune effector cells. Our approach is to expand cellular engineering and immunotherapy research by bringing together physicians and laboratory scientists focused on immune cell engineering and its clinical effects. We aim to enhance the cohesion between biological, translational, and clinical aspects of cell engineering to implement safe and potent immunotherapies, with the ultimate goal of developing curative treatments for cancer and other diseases.
We aim to enhance the cohesion between biological, translational, and clinical aspects of cell engineering to implement safe and potent immunotherapies.
- Bring together clinical researchers who administer, manage, and/or investigate immune effector cells as a therapeutic modality
- Enable translational research and collaboration
- Optimize immune monitoring and laboratory correlatives of clinical observations
- Promote cellular therapy education through education sessions
- Provide high quality care and management of patients receiving cellular therapies
- Obtain and maintain FACT accreditation for the administration of immune effector cells
- Invent and develop novel forms of cellular engineering that will become the next generation of immune cell therapies
CAR T-Cell Therapies
Mass General Cancer Center is an authorized treatment center for FDA approved CAR T-cell therapies for adult patients with lymphoma (Breyanzi, Kymriah, Tecartus and Yescarta) and for adult patients with multiple myeloma (Abecma). Learn more.
Meet the Team
Lead by Marcela Maus, MD, PhD, the Cellular Immunotherapy Program brings together physicians and laboratory scientists focused on immune cell engineering and its clinical effects.
- Director, Cellular Immunotherapy Program
- Associate Professor of Medicine, Harvard Medical School
Learn about the Cellular Therapy & Transplantation Laboratory.
Honors & Awards
View Cellular Immunotherapy Program team members honored for their commitment to the fight against cancer.
Marcela V. Maus, MD, PhD
As the director of the Cellular Immunotherapy Program at the Mass General Cancer Center, Marcela Maus, MD, PhD, is following a childhood dream of fixing genes gone wrong in the pursuit of a cure for cancer.
Cellular Therapy and Transplantation Laboratory
The CTTL team plays an integral part in stem cell processing, transplant infusions and bone marrow harvests. Technologists also participate in numerous immunotherapy clinical trials to aid in the progression of research and improve patients’ lives.
- Immune therapy takes a 'BiTE' out of brain cancer
- The Solid Tumor Barrier
- Researchers Explore CAR-T Cells’ Potential
- Cancer Researcher Teamed Up With Superheroes
- Immunotherapy Effort Seeks New Cancer Targets
- CAR-T engineering of patients’ own T cells for cancer therapy gains traction
- For Some, Cutting-Edge 'CAR-T' Treatment Unleashes 'Pac-Man' Cells Against Blood Cancer
- Guest commentary: Early trials support use of CAR T-cell therapy in glioblastoma
- Stand Up To Cancer Awards Innovative Research Grants in Immuno-oncology to 10 Early-career Scientists
Related News and Articles
- Press Release
- Apr | 28 | 2022
A chimeric antigen receptor (CAR) T-cell construct designed to overcome difficulties with prior attempts showed good efficacy against AML in mouse models.